Targeting the elevated expression of LAG-3 on CD8+ and CD4+ T cells in the blood and bone marrow of patients with multiple myeloma will help enhance the proliferative and anti-tumor capacity of T cells [91]. This evidence concerns the gene LAG3 and neoplasm.